All authors have read and approved the final version and publication of the manuscript.
Retatrutide Phase 3 Results: What the 2026 Clinical Data Actually Shows Rob Lagana Jun 21 5 min read The published retatrutide phase 3 results have, in the span of three months, reshaped what is clinically known about triple-agonist therapy
The Journal of Clinical Endocrinology & Metabolism, 91 (9), 35043511
semaglutide comparison after three years of head-to-head publications in one line, it would be this: at the pivotal dose and at 60-72 weeks, the average weight loss shows a clear progression from semaglutide to retatrutide
This flat-rate model removes the cost barrier to dose optimization, so you and your PlexusDx clinician can focus on finding your ideal dose without worrying about escalating monthly bills
For someone weighing 200 pounds, thats 30 to 40 pounds of weight loss